CD86 and neoplasm: CTLA4, a T-cell co-stimulatory molecule, primarily functions by binding with co-stimulatory molecules CD80/CD86, thereby inhibiting T-cell activity and weakening immune response [42], ultimately promoting tumor growth and metastasis [43].